ABMC Reports First Quarter 2013 Results

ABMC Reports First Quarter 2013 Results

KINDERHOOK, N.Y.--(BUSINESS WIRE)-- American Bio Medica Corporation (ABMC.PK) today announced financial results for the three months ended March 31, 2013.

Net sales for the first quarter of 2013 were $2,125,000, a decrease of $171,000, or 7.4%, when compared to net sales of $2,296,000 for the first quarter of 2012. Operating loss for the first quarter of 2013 was $362,000, compared to an operating loss of $169,000 in the first quarter of 2012. Net loss for the first quarter of 2013 was $424,000, or $0.02 per share, compared to a net loss of $206,000, or $0.01 per share reported in the first quarter of 2012.

ABMC Chief Executive Officer Stan Cipkowski stated, "Achieving sales growth in the drug testing market remained challenging in the first quarter of 2013, as drug testing budgets in the private and public sectors continue to be affected by uncertain economic conditions and high unemployment rates."

Cipkowski continued, "General and administrative expense continues to be impacted by investments in the required regulatory costs associated with our efforts to get FDA 510(k) marketing clearance on oral fluid and other new products, as well as ongoing litigation. Diversification continues to be our primary objective in 2013."

For more information on ABMC or its drug testing products, please visit www.abmc.com.

About American Bio Medica Corporation

American Bio Medica Corporation develops, manufactures and markets accurate, cost-effective immunoassay test kits, primarily point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets.ABMC's Rapid Drug Screen®, Rapid ONE®, RDS® InCup®, Rapid TOX® and Rapid TOX Cup® II test for the presence or absence of drugs of abuse in urine, while OralStat® and Rapid STAT™ test for the presence or absence of drugs of abuse in oral fluids. ABMC's Rapid Reader® is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.

This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, risks and uncertainties related to the following: continued acceptance of our products, increased levels of competition in our industry, acceptance of new products, product development, compliance with regulatory requirements, intellectual property rights, our dependence on key personnel, third party sales and suppliers, trading in our common shares may be subject to "penny stock" rules, our history of recurring net losses and our ability to continue as a going concern. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled "Risk Factors" in the Company's annual report on Form 10-K for the year ended December 31, 2012, quarterly reports on Form 10-Q, and other periodic reports on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares.

Condensed Statements of Operations
 For the three For the three
months endedmonths ended
March 31, 2013March 31, 2012
Net sales$2,125,000$2,296,000
Cost of goods sold1,339,000  1,334,000 
Gross profit786,000962,000
Operating expenses:
Research and development63,00052,000
Selling and marketing475,000521,000
General and administrative610,000  558,000 
Total operating expenses1,148,0001,131,000
Operating loss(362,000)(169,000)
Other expense(61,000) (42,000)
Net loss before tax(211,000)
Income tax expense / (benefit)(1,000) 5,000 
Net loss$(424,000)$(206,000)
Basic & diluted loss per common share$(0.02)$(0.01)
Basic & diluted weighted average shares outstanding22,166,33621,744,768
American Bio Medica Corporation
Condensed Balance Sheets
 March 31,December 31,


Current Assets
Cash and cash equivalents$1,000$89,000
Accounts receivable, net of allowance for doubtful accounts of $59,000 at March 31, 2013 and $60,000 at December 31, 2012



Inventory, net of allowance for slow moving and obsolete inventory of $304,000 at March 31, 2013 and $261,000 at December 31, 2012



Prepaid expenses and other current assets159,000  50,000 
Total current assets3,545,0003,520,000
Property, plant and equipment, net1,175,0001,192,000
Debt issuance costs, net401,00029,000
Other assets14,000  14,000 
Total assets$5,158,000 $ 4,779,000 
Current liabilities
Accounts payable698,000$1,016,000
Accrued expenses and other current liabilities191,000174,000
Wages payable214,000231,000
Line of credit1,176,000321,000
Current portion of long-term debt1,348,000  1,404,000 
Total current liabilities3,627,0003,146,000
Other liabilities145,000145,000
Related party note124,000  124,000 
Total liabilities3,896,0003,415,000
Stockholders' Equity:
Common stock222,000218,000
Additional paid-in capital19,809,00019,490,000
Accumulated deficit(18,769,000) (18,344,000)
Total stockholders' equity1,262,000  1,364,000 
Total liabilities and stockholders' equity$5,158,000 $$4,779,000 

American Bio Medica Corporation
Stan Cipkowski, 800-227-1243, Ext 106
Chief Executive Officer

KEYWORDS:   United States  North America  New York


The article ABMC Reports First Quarter 2013 Results originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story